Search
Alprazolam
go.drugbank.com/drugs/DB00404ApprovedIllicitInvestigationalAlprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole. Benzodiazepine trea...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRemoxipride
go.drugbank.com/drugs/DB00409ApprovedWithdrawnRemoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsRosiglitazone
go.drugbank.com/drugs/DB00412ApprovedInvestigationalRosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepirid...
Synonyms: (±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedioneCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersAmpicillin
go.drugbank.com/drugs/DB00415ApprovedInvestigationalVet approvedAmpicillin is a semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.
Entecavir
go.drugbank.com/drugs/DB00442ApprovedInvestigationalEntecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS). Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesTenoxicam
go.drugbank.com/drugs/DB00469ApprovedInvestigationalTenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesLenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigationalLenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of thalidomide and like thalidomide, lenalidomi...
Categories: P-glycoprotein substratesSotalol
go.drugbank.com/drugs/DB00489ApprovedInvestigationalSotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tabl...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesBuspirone
go.drugbank.com/drugs/DB00490ApprovedInvestigationalBuspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT1A receptor agonist that is not chemically or pharmacologically re...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesEntacapone
go.drugbank.com/drugs/DB00494ApprovedInvestigationalEntacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxyl...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors